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ABSTRACT
Objective: The objective of the present study was to assess
the impact of depression on patients’ health-related quality
of life (HRQL) with the EQ-5D instrument over 6 months
while on antidepressant treatment.
Methods: A total of 447 patients were recruited at 56 pri-
mary care centers to this naturalistic longitudinal observa-
tional study. Patients older than 18 years with depressive
symptoms, and who initiated an antidepressant therapy
because of depression were included in the study. Data on
patients’ sociodemographics, daily activity, and quality of life
(EQ-5D) were collected using questionnaires completed dur-
ing outpatient general practitioner visits for a follow-up
period of 6 months.
Results: The mean EQ-5D utility score at baseline was 0.47
(0.44–0.49). Milder cases of depression reported a health
utility of 0.60, whereas moderately and severely depressed
patients reported utility values of 0.46 and 0.27, respectively
(P < 0.01). At end of follow up the average utility was 0.69
(0.67–0.72), corresponding to an increase of 0.23 over
6 months (P < 0.01). Regression analyses showed that, all
else equal, patients who were on sick leave were associated
with 10% lower utility.
Conclusions: Depression has a substantial impact on
HRQL. Our results indicate that treatments for depression
are associated with signiﬁcant improvement in EQ-5D index
score over a course of 6 months. Self-reported patient valu-
ations are important outcomes for cost-utility analysis of
new treatments for depression and the present study provides
important evidence for future economic evaluations.
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Introduction
Depression is common in primary care patients with
an approximate lifetime prevalence of 40% in women
and 20% in men [1]. Depression is usually associated
with loss of interest or pleasure in previously enjoyed
activities  and  is  associated  with  marked  decreases
in functioning, well-being and health-related quality
of life (HRQL). Previous research has shown that
patients with major depressive disorder report sub-
stantial impairments in physical, psychological, and
social functioning [2–8].
HRQL is a concept reﬂecting an individual’s sub-
jective perceptions and experiences. Impaired quality
of life denotes functional limitations and perceived dif-
ﬁculties in everyday life caused by a disease or illness.
HRQL is hence a complement to health status exam-
ination of patients with physical or mental illness.
Quality of life as a generic outcome measure is recom-
mended in assessing the cost-effectiveness of new inter-
ventions. For this purpose, HRQL measurements have
to enable the expression of patient health status on a
scale between 0 and 1, where 0 signiﬁes death and 1
perfect health. The summary index score of the EQ-5D
instrument has become a standard measure for assess-
ing the quality of life in a wide variety of patient
populations, and is commonly used for calculating
quality-adjusted life-years (QALYs) in economic eval-
uations [9]. To calculate patient preference utility
weights (index scores) from the answers to the EQ-5D
instrument, population-based social tariffs are usually
employed, that is, tariffs based on health state valua-
tions in general population samples.
There are, however, only a few previous observa-
tional studies having employed the EQ-5D instrument
to assess the HRQL of patients with depression
[6,8,10,11], Sapin et al. assessed quality of life in
patients treated for major depressive disorder in an
observational study in French primary care setting
[11]. The study was, however, only following patients
for 2 months and hence it is a rather short period of
time to judge upon improvements in quality of life
from treatment. Peveler et al. conducted a randomized
controlled observational study of a sample of
Sobocki et al.154
depressed patients in a UK primary care setting, assess-
ing quality of life with the EQ-5D instrument [10]. The
EQ-5D instrument was, however, only a secondary
outcome measure and the design of this study was
different from the present. Consequently, the present
study appears to be the ﬁrst to measure EQ-5D index
score changes over a longer term in patients treated for
depression in primary care.
Antidepressant  treatments  are  effective  in  reduc-
ing depressive symptoms and previous studies have
shown substantial improvements measured in HRQL
[6,8,10,11]. The assessment of HRQL is, however, sel-
dom conducted in naturalistic settings and therefore
not reﬂecting the use, management, and effects of
treatment as they appear in clinical practice.
The objectives of this article are to describe the
impact on quality of life, measured with the EQ-5D
instrument, of patients with depression initiating anti-
depressants treatment in selected primary care settings
and the impact of treatment over a period of
6 months.
Materials and Methods
Study Design
A total of 447 patients with depression were enrolled
in this naturalistic prospective longitudinal observa-
tional study. Subjects were recruited attending regular
general practitioner visits at 56 primary care centers in
ﬁve different regions of Sweden. Patients older than
18 years with a diagnosis of depression (according to
the diagnostic criteria utilized in clinical practice by the
participating centers) who initiated a new treatment
with antidepressants for their depressive symptoms
were eligible for inclusion. Study protocols were
approved by ﬁve local ethics committees in the regions
concerned, and informed consent was obtained from
patients before inclusion. Because this study was nat-
uralistic, the choice of antidepressant treatment was
entirely controlled by the physician, and thus con-
comitant treatments (e.g., psychotherapy) were also
provided alongside antidepressant treatment. The
intention was to capture the treatment of depression as
it is actually performed in primary care in Sweden, and
the study was designed to interfere as little as possible
with the normal course of clinical work. Data were
collected by the treating physician through a ques-
tionnaire at baseline, and at follow-up visits until
6 months.
Data Collection
The present study was designed as prospective and lon-
gitudinal with respect to the collection data. The inclu-
sion criteria in the study were: 1) age above 18 years;
2)  patient  suffers  from  depression;  and  3)  patient
had initiated antidepressant treatment for depression.
Patients were excluded if, because of illness or other
reasons, they would not be able to participate in the
survey in an adequate way. Patients who fulﬁlled the
inclusion and exclusion criteria were enrolled consec-
utively at each clinic, provided that they consented to
participate in the study. The period of active recruit-
ment was 12 months, followed by 6 months of follow
up for each patient.
Treating physicians included in the study recorded
information about enrolled patients to the study. At
baseline, the following information were collected:
sociodemographics (age, sex, civil status, and educa-
tional level), clinical information (comorbidities, sui-
cidal tendency, and depression severity), treatment
history, and daily activity. At each revisit data were, in
addition, recorded on improvement from treatment
since last visit, antidepressant treatment changes since
last visit (titration, switches, cessation, and combina-
tion treatments), medical visits, hospitalizations, and
visits to other health professionals and use of other
treatments (psychotherapy, other drug treatments)
since last visit. The patients also completed the Euro-
QoL (EQ-5D)  health  status  questionnaire  at  each
visit [12]. The EQ-5D questionnaire consists of ﬁve
domains concerning the patient’s mobility, hygiene,
daily activity, pain, and anxiety and depression. Clin-
ical severity was assessed with the Clinical Global
Impression Scale on Severity (CGI-S) [13], which is a
seven point scale ranging from 1 (“Normal”) to 7
(“Among the most extremely ill patients”). Treatment
improvement in patients was assessed through physi-
cian’s judgment on patient status at each revisit com-
bined with an assessment with the Clinical Global
Impression Improvement Scale (CGI-I) [13]. The CGI
instruments employed in the present study have previ-
ously been used in similar studies [11,14].
Statistical Analysis
In the absence of speciﬁc social tariffs for Sweden at
the time of conducting this study, the EQ-5D index tar-
iffs derived by Dolan et al. were employed [15]. The
Dolan regression model for calculating EQ-5D index
scores from the instrument generated values on a car-
dinal scale from 0 to 1. Nevertheless, it also generates
negative values where a cutoff was set at −1 [15]. Con-
sequently, it may be difﬁcult to interpret the negative
values that are calculated from these tariffs, and it has
been argued that negative values should be set to zero
[16,17].
The Shapiro-Wilk’s test was used for testing the
normality of the distributions of the data for HRQL
[18], which was found to be non-normally distributed.
Hence, the nonparametric Kruskal–Wallis one-way
analysis of variance test was used [18] to test the dif-
ference in quality of life by demographic and clinical
characteristics. Conﬁdence intervals were calculated
using the bias-corrected accelerated (bca) percentile
bootstrapping method [19,20].
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A multivariate ordinary least squares regression
model was speciﬁed using the step-wise method to
explore the determinants of utility. Independent varia-
bles included in the speciﬁed regression model were:
treatment response status (measured as clinical remis-
sion at end of follow up), comorbidity (reported at
inclusion), suicidal tendency (reported during follow
up),  sick  leave  status  (reported  during  follow-up)
and severity of depression (assessed at baseline). The
Breusch-Pagan test was used to test for heteroscedas-
ticity [21]. In presence of heteroscedasticity, White’s
corrected standard errors were applied [21]. The spec-
iﬁcation of the model was tested with the Ramsey
RESET test [21]. A 5% risk of type I error was
employed as the level of statistical signiﬁcance
throughout the study.
All statistical analyses were performed using STATA
8.0 for Windows (StataCorp., College Station, TX,
USA).
Results
Patient Characteristics
Patient age ranged from 18 to 89 years and the mean
age was 47 years (SD 14.2), and 67% of the patients
were women. The mean duration of the present epi-
sode of depression was 148 days (SD 74), and a major-
ity (77%) of the patients had just been diagnosed for a
new episode of depression at the time of inclusion in
the study. The majority of the patients was married/
cohabiting, and had completed at least high school
education. The mean CGI-S score in the sample was
3.9 (SD 0.74) measured on a scale from 1 to 7, and
24% of the patients in the sample had mild depression
(CGI-S score 2–3), 60% moderate depression (CGI-S
score 4) and 16% severe depression (CGI-S score 5–7).
Comorbidities were common; 59% of the patients
had at least one type of comorbidity. Physical comor-
bidities, most commonly cardiovascular diseases and
migraine, were reported in 56% of the patients, and
psychiatric comorbidities, most commonly anxiety dis-
orders and alcohol dependence, in 9% of the patients.
Suicidal tendency was reported by 7% of the patients.
Among patients aged below 65 years, 67% of were
working, and among the nonworking patients in the
sample, 23% were unemployed. All patients initiated
antidepressant treatment at inclusion and 8% of the
patients also had psychotherapy. The only statistically
signiﬁcant difference between men and women was in
working proportion. The demographic and clinical
characteristics of the study sample are summarized in
Table 1.
Out of the total number of patients enrolled in the
study, 21 patients dropped out before the index visit,
and hence baseline information was available for 426
patients (95%). Another 32 patients dropped out dur-
ing the ﬁrst follow-up visit or had incomplete response
on the EQ-5D questionnaire. Their demographic and
clinical characteristics were not signiﬁcantly different
from those of the 394 completers (88%).
EQ-5D Index Score from Baseline to Last Visit
The baseline EQ-5D index score was 0.47 (0.44–0.50)
and ranged from 0 to 1 (see Table 2). Out of the ﬁve
domains in the EQ-5D instrument, depression seems to
have an impact mainly on domain 3, 4, and 5. Domain
3  concerns  usual  activities,  domain  4  the  level  of
pain and discomfort experienced by the patient, and
domain 5 the level of anxiety and depression. Pair-wise
correlations of the individual domains with EQ-5D
index score indicate that all EQ-5D domains are neg-
atively correlated with the EQ-5D index score accord-
ing to our expectations (P < 0.01). Moreover, the
correlations conﬁrm the strong association between
domains 3–5 and the EQ-5D index score.
During the ﬁrst follow-up visit, the patient-pre-
ferred utility increased to 0.60 and at approximately
6 months follow up it reached 0.66 (a paired difference
of 0.20). The development of the EQ-5D index score
during the follow-up period is depicted in Figure 1.
The differences in utility scores to baseline are statis-
tically signiﬁcant (P < 0.01) up to follow-up visit 5 in
the study (approximately 6 months). Because patients
have individual follow-up times, the average of the
EQ-5D index scores at the last study visit was calcu-
lated, and had a mean value of 0.69 (0.67–0.72).
Table 1 Patient characteristics
Characteristics Men Women Total
No. of patients 149 298 447
Mean age (years) 45.7 47.9 47.1
Age range (years) 18–84 18–89 18–89
New episode at inclusion (%) 80 76 77
Mean follow-up time (days) 144 150 148
Follow-up time range (days) 0–426 0–354 0–426
Civil status (%)
Single 27.5 23.8 25.1
Married/cohabitating 63.8 58.7 60.4
Divorced 6.0 11.7 9.8
Widow/ed 2.7 5.7 4.7
Education (%)
Below high school 23.5 24.8 24.4
Completed high school 42.3 46.6 45.2
Completed college or university 34.2 28.5 30.4
Depression severity at inclusion (%)
Mild (CGI-S score 1–3) 28.9 22.5 24.6
Moderate (CGI-S score 4) 55.7 62.1 60.0
Severe (CGI-S score 5–7) 15.4 15.4 15.4
Comorbidity (%) 58.5 58.8 58.7
Psychiatric comorbidity 12.0 7.7 9.2
Physical comorbidity 54.0 56.7 56.1
Working (%) 59.2 70.8 66.9
Full time 86.9 69.2 74.4
Part time 13.1 30.8 25.6
Nonworking status (%) 40.8 29.2 33.1
Unemployed 31.0 18.1 23.4
Early retirement 10.3 18.1 14.9
Long-term sickness leave 17.2 13.3 14.9
Age pension 27.6 38.6 34.0
Studying 13.8 12.0 12.8
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Hence, the difference to the average baseline utility
was 0.23 (0.19–0.26), which was statistically signiﬁ-
cant (P < 0.01). Another way of presenting the devel-
opment of the HRQL during follow up in our sample
is to group the EQ-5D index scores by 3-month peri-
ods. During the ﬁrst 3 months of follow up, the mean
utility score has increased to 0.59 (0.56–0.61) fol-
lowed by 0.65 (0.62–0.68) during the second 3-month
period of follow-up. The increase in utility was statis-
tically signiﬁcant to baseline both for the 3-month and
6-month periods (P < 0.01).
Comparison of EQ-5D Index Score with 
Demographic Variables
Men and women reported similar EQ-5D index scores
at baseline: 0.49 (0.43–0.53) and 0.46 (0.42–0.49),
respectively, and the small difference remained at the
last visit of follow-up. Patients aged below 65 years
reported lower utility scores than patients aged more
than 65 years, although the difference was not statis-
tically signiﬁcant at the 5% level. The same pattern
was seen at the end of follow-up. Moreover, patients
with higher education reported higher utility scores
than patients who only had obtained a high-school
degree. At the last follow-up visit the difference was
statistically signiﬁcant (P < 0.05). Patients who lived
alone scored higher on the EQ-5D instrument com-
pared with those living together with someone.
Nevertheless, the difference was neither statistically
signiﬁcant at baseline nor at the last follow-up visit.
The results are summarized in Table 3.
Comparison of EQ-5D Index Score by Clinical Variables
The presence of comorbidity in patients with depres-
sion had an impact on the EQ-5D index score, with
Table 2 EQ-5D index values by visit
Baseline
Visits 
1 2 3 4 5
No. of patients 394 378 287 133 59 28
EQ-5D: 1 1.1 1.1 1.1 1.1 1.1 1.1
EQ-5D: 2 1.0 1.0 1.0 1.0 1.0 1.0
EQ-5D: 3 1.9 1.7 1.6 1.7 1.8 1.9
EQ-5D: 4 1.9 1.8 1.7 1.5 1.6 1.5
EQ-5D: 5 2.4 2.0 1.8 1.8 1.9 1.9
EQ-5D index score 0.47 0.60 0.66 0.70 0.66 0.66
95% conﬁdence interval 0.44–0.50 0.57–0.62 0.63–0.69 0.66–0.74 0.58–0.73 0.53–0.75
VAS 40 53 62 67 66 63
Difference to baseline (unpaired) — 0.13* 0.19* 0.23* 0.19* 0.20*
Difference to baseline (paired) — 0.13* 0.21* 0.25* 0.24* 0.26*
Mean follow up (days) 0 61 121 148 151 165
*P < 0.01.
Figure 1 Average EQ-5D index values over time (visits). Vertical lines:
95% conﬁdence intervals for the utility.
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Table 3 Difference in EQ-5D index values by demographic characteristics
Baseline Last visit Difference 
Mean 95% CI P-value Mean 95% CI P-value Mean 95% CI P-value
Sex 0.2626 0.2616 0.7600
Male 0.49 0.43–0.53 0.72 0.67–0.76 0.23 0.18–0.29
Female 0.46 0.42–0.49 0.68 0.65–0.72 0.22 0.18–0.27
Age group (years) 0.0971 0.3482 0.0765
18–64 0.46 0.40–0.48 0.70 0.67–0.73 0.24 0.20–0.27
65 or above 0.52 0.46–0.54 0.67 0.57–0.74 0.15 0.07–0.24
Educational level 0.3388 0.0288 0.5578
High school 0.46 0.43–0.49 0.68 0.64–0.71 0.22 0.18–0.26
Higher education 0.49 0.43–0.54 0.73 0.68–0.77 0.24 0.19–0.29
Civil status 0.0949 0.2344 0.0200
Single/divorced 0.47 0.44–0.50 0.70 0.67–0.72 0.23 0.18–0.28
Married/coliving 0.39 0.30–0.48 0.66 0.55–0.74 0.27 0.23–0.31
CI, conﬁdence interval.
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baseline scores of 0.45 for patients with comorbidity,
and 0.49 for patients without. The difference was even
greater at the last visit (0.13) of follow-up and was sta-
tistically signiﬁcant (P < 0.01). Signiﬁcant differences
in EQ-5D index scores were also found by disease
severity assessed by CGI-S, with more severely
depressed patients reporting lower utility than milder
cases of depression. Patients with mild depression
(CGI-S level 2–3) reported an average utility score of
0.14 higher than moderately depressed patients at
baseline (P < 0.01) and a difference of 0.07 (P < 0.05)
at the end of follow-up, corresponding to a mean
utility value of 0.76. Moderately depressed patients
reported an average utility of 0.46 at baseline and 0.69
at the end of follow-up, which can be compared with
the results for the most severe cases of depression with
utility  scores  of  0.27  and  0.62  at  baseline  and  end
of follow-up, respectively. The differences in EQ-5D
index scores between moderate and severe cases of
depression were, however, only signiﬁcant at baseline
(P < 0.01). Patients who had combined pharmacolog-
ical treatment with psychotherapy reported higher
utility scores than patients only treated with antide-
pressants, but the differences at baseline and the last
visit of follow up were not statistically signiﬁcant. The
results are presented in Table 4.
Determinants of EQ-5D Index Score
In a multivariate linear regression analysis, the EQ-5D
index score was used as the dependent variable and the
following independent variables were included in the
speciﬁed model: sick leave status (dummy), disease
severity (dummy where severe depression was set to 1),
remission (dummy), suicidal tendency (dummy) and
comorbidity (dummy). The speciﬁcation of the regres-
sion model was made on the pooled data where all
data points over time were taken into account. The
regression model was hence clustered for multiple
observations per patient. To investigate whether there
were differences in the results over time the speciﬁed
model was also employed on data grouped by 3-month
periods. Table 5 presents the estimated regression coef-
ﬁcients of the explanatory variables included in the
model. The regression model explained 23% of the
variation in utility. The coefﬁcients from the speciﬁed
regression model all went in the expected directions.
Patient who achieved clinical remission during the
study period reported a 26% higher utility score (all
else equal). Moreover, patients on sick leave because of
their depressive episode (at any time throughout the
follow-up period) were associated with 6% lower util-
ity. Patients with severe depression had a utility reduc-
tion of 10% compared with mild or moderate cases.
The regression analysis also showed that patients with
mental and/or physical comorbidity were associated
with decreased utility (7%), and that patients who
reported suicidal tendency were associated with lower
utility. Pair-wise correlations between dependent vari-
ables showed a correlation of 0.12 between sick leave
and depression severity, 0.05 between comorbidity and
Table 4 Difference in EQ-5D index values by clinical characteristics
Baseline Last visit Difference 
Mean 95% CI P-value Mean 95% CI P-value Mean 95% CI P-value
Psychotherapy 0.1548 0.5520 0.0714
Yes 0.51 0.43–0.59 0.66 0.67–0.73 0.15 0.06–0.24
No 0.46 0.43–0.49 0.70 0.58–0.73 0.24 0.20–0.27
Comorbidity 0.1895 0.0001 0.0051
Yes 0.45 0.42–0.49 0.64 0.60–0.68 0.19 0.15–0.23
No 0.49 0.45–0.53 0.77 0.73–0.80 0.28 0.23–0.33
Depression severity at inclusion 0.0001 0.0075 0.0015
Mild 0.60 0.54–0.65 0.76 0.71–0.81 0.16 0.11–0.23
Moderate 0.46 0.30–0.48 0.69 0.65–0.72 0.22 0.18–0.26
Severe 0.27 0.21–0.34 0.62 0.52–0.69 0.35 0.25–0.44
CI, conﬁdence interval.
Table 5 Regression on EQ-5D index value
Baseline 0–3 months 3–6 months All periods*
Coefﬁcient P-value Coefﬁcient P-value Coefﬁcient P-value Coefﬁcient P-value
Remission — — 0.2596 <0.0001 0.2182 <0.0001 0.2635 <0.0001
On sick leave −0.0689 <0.0001 −0.0541 0.0170 −0.0866 0.0080 −0.0615 0.0010
Severe depression −0.2173 <0.0001 −0.1374 <0.0001 −0.0579 0.3810 −0.0953 0.0030
Comorbidity −0.0334 0.2370 −0.0454 0.0610 −0.1262 <0.0001 −0.0731 <0.0001
Suicidal tendency −0.0621 0.3090 −0.1492 0.0070 −0.1492 <0.0001 −0.1938 <0.0001
(constant) 0.5414 <0.0001 0.5762 <0.0001 −0.0866 0.0324 0.6072 <0.0001
R2 0.0981 0.1604 0.3276 0.2342
*Standard errors adjusted for clustering.
Remission: Patients who achieved ﬁrst remission during follow up assessed with CGI-I combined with judgment from treating physician.
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depression severity, −0.14 between depression severity
and clinical remission, and −0.07 between sick leave
and clinical remission.
The speciﬁed regression model showed the same
patterns when only including information about the
patient at baseline or 3-month follow-up data. Comor-
bidity was not statistically signiﬁcant at baseline or
during the ﬁrst quarter of the follow-up period, but
had a signiﬁcant negative impact on the quality of life
in the second quarter, that is, for the second 3-month
period.  Disease  severity  was  not  signiﬁcant  during
the ﬁrst and second 3-month periods, respectively. The
regression results were, moreover, not changing very
much when only including patients with severe depres-
sion, except for an association between reported EQ-
5D scores and achieving clinical remission (39%).
Discussion
Our results show that depression has a substantial
impact on the patient’s HRQL. Moreover, we ﬁnd that
antidepressant treatment for depression is associated
with a 50% improvement in HRQL over a course of
6 months. Our results also indicate that the generic
EQ-5D instrument is a potentially useful instrument to
assess the preference-based quality of life in depressed
patients treated in a primary care setting for calcula-
tions of QALYs in economic evaluations of treatments
for depression. There is no previous prospective obser-
vational study measuring the patient-assigned health
utility with the EuroQol instrument in treated subjects
with depression in Sweden, and only a few studies are
available for other countries.
There are several limitations to this study that
should be taken into account when interpreting our
results. First, our study was restricted to patients
treated in primary care setting, which means that the
results cannot necessarily be generalized to other set-
tings, for example, outpatient psychiatric care. Second,
our assessment of HRQL did not speciﬁcally take side-
effects of treatments of depression into account, and
hence it is not possible to assess possible disutility
effects from adverse reactions of treatments in our
material. Third, as a result of the design of the study
we cannot tell to what extent the increase in quality of
life was due to antidepressant treatment exclusively,
because concomitant treatments were given in combi-
nation (e.g., psychotherapy). Finally, the design of this
study was naturalistic and thus the data collection was
meant to intervene as little as possible in the clinical
work. Consequently, no formal diagnostic assessment
was made at inclusion and relatively simple instru-
ments were employed to assess the patients’ severity of
depression (CGI-S scale) and improvement during the
course of treatment (CGI-I scale), and although the
instruments are validated and have been used in simi-
lar previous research more thorough instruments could
have improved the accuracy in measuring the severity
of depression.
Our results show that HRQL, as measured with
EQ-5D, for people with depression is almost 60%
lower compared with the average person in the general
population [17,22]. A study by Isacson et al. assessed
the HRQL in depressed patients with the SF-36 instru-
ment, and reported an average score of 44 (out of 100)
[22], which is in line with our results. Burström et al.
investigated the EQ-5D index value in the general pop-
ulation and showed that mental distress was one of the
disease areas with the lowest average utility values, in
the same range as patients with angina pectoris [17].
There are only a few international observational
studies where the HRQL in depressed patients has
been assessed with the EQ-5D instrument. Sapin et al.
conducted a 2-month observational study in French
primary care setting including patients with major
depressive disorder [11]. They found a mean EQ-5D
index value at baseline of 0.33. Their study, however,
included a smaller sample with more severe depression
as compared with our study population. If the EQ-5D
index scores are matched by CGI-S level with our
study population, the results are similar. Peveler et al.
reported a baseline EQ-5D index value of 0.59 in a
sample of depressed patients in a UK primary care
setting [10].
We reported an average utility value of 0.69 at end
of follow up, which is in agreement with previous
assessments with the EQ-5D index scores at follow up
for depressed patients treated with antidepressant [8].
Nevertheless, comparisons should be made with pre-
caution, because previous studies are of different
designs and with somewhat different patient popula-
tions and follow-up periods, it indicates that anti-
depressant treatments may have a substantial
improvement on quality of life in depressed patients, in
the range of 50%.
Our study found no differences in EQ-5D utility by
demographic variables at baseline, which is in con-
cordance with previous research [8,11,23]. At end of
follow up, however, we observed a signiﬁcant differ-
ence in utility scores by educational level. Stratifying
the results by clinical characteristics, we ﬁnd that more
severely depressed patients reported signiﬁcantly lower
utility values than less severe cases both at baseline
and at end of follow up. The most severely depressed
patients reported an average EQ-5D index value of
0.27, compared with 0.46 and 0.60 for moderate and
mild cases, and thus the difference is clearly clinically
relevant [24,25]. At end of follow up the EQ-5D index
scores by disease severity were closer, but the differ-
ence was still statistically signiﬁcant. Earlier studies
have also found that EQ-5D index scores are statisti-
cally different by severity level of depression [2,8,11].
The explanatory variables selected for the regres-
sion model speciﬁed explained 23% of the variance in
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the EQ-5D index value, which is similar to studies
conducted on the quality of life assessed with EQ-5D
[11,26]. In our study, demographic variables did not
signiﬁcantly explain the variation in EQ-5D index
score in depressed patients, which is in line with pre-
vious ﬁndings [8,11]. Our results indicate, however,
that by preventing depressed patients from having to
leave the workforce, temporarily or for the longer
term, positive effects on their quality of life may be
obtained. Few previous studies in the literature have
investigated this relationship, which makes it an inter-
esting topic for further research. The causality is,
however, debatable from this ﬁnding, and it can be
expected that sick leave is a proxy for more disabling
cases of depression. Our data do, however, not show
any evidence for signiﬁcantly more severe cases of
depression among patients who were on sick leave as
compared with less severely depressed patients. Treat-
ing the patient until achieving clinical remission from
the depressive episode is also associated with a signif-
icantly higher EQ-5D index score, which has been
observed in previous research [8,11]. We have already
seen that the severity of the depression affects the util-
ity values signiﬁcantly, and the regression analysis con-
ﬁrms this ﬁnding. Lastly, our regression analysis shows
that patients who have suicidal tendency because of
their depression are associated with a rather low
decrease in EQ-5D index score. The result is, however,
according to our expectations considering the rela-
tively mildly depressed study population.
The calculations of EQ-5D index score did not
allow for negative values in our study, because the
interpretation of negative index values is in our view
questionable, not the least in light of the methodolog-
ical background of the EQ-5D index tariff. A cutoff
point at zero has also been applied to the EQ-5D index
tariff  in  previous  similar  studies  [17,27].  It  could
be interesting, however, to allow for negative scores
because one could hypothetically argue that for
instance suicidal or severely depressed patients have a
health state worse than death (which represents nega-
tive utility score). Allowing for this, 8% of the patients
in our sample rated their health state as worse than
death, which is similar to results obtained by Sapin
et al. [11]. Recalculating average EQ-5D index scores
in the present study, does however, change the results
only marginally and hence has little impact on the con-
clusions drawn from the results from the present study.
The tariffs produced by Dolan et al. were employed
in this study, to calculate utility scores, because there
exist no similar survey in Sweden [15]. These are
referred to as social tariffs, because they are based on
health state valuations in a general population sample.
It is, however, debatable whether this is the most
appropriate approach. The alternative would be to
base the valuations on individuals who are actually in
the health state (i.e., depressed patients). Because no
speciﬁc elicitation of the individual tariffs of depressed
patients exists in the literature, no comparison of
results employing this alternative approach could be
made. One application of EQ-5D index values is, how-
ever, for economic evaluations, and there is an indica-
tion in the literature suggesting that the use of the
social tariffs would result in overestimated gains in
QALYs compared with individual values [28], which
should be kept in mind when using the results from the
present study for cost-effectiveness analysis in future.
HRQL was assessed only with the EQ-5D instru-
ment in the present study; because of the scope and
time restrictions in the data collection no additional
instruments were employed. Moreover, the study
intended to interfere as little as possible with clinical
practice and having included more HRQL instru-
ments in the assessment could have compromised fur-
ther with this intention. The EQ-5D instrument is a
generic one and therefore it is possible that some
aspects of the impact of depression on quality of life
were not picked up properly. Nevertheless, our results
show that depression had impact on three out of ﬁve
domains on the EQ-5D instrument, of which the ﬁfth
domain exclusively assesses symptoms of anxiety and
depression.
Conclusions
Depression has a substantial impact on the HRQL of
the patient, as measured with the EQ-5D instrument.
Our results indicate that treatments for depression are
associated with a signiﬁcant improvement in EQ-5D
index score over a course of 6 months. The improve-
ment is in the range of 50%. A substantial improve-
ment in EQ-5D index score was seen when patients
remit from their depressive symptoms. Moreover,
quality of life decreases with increased severity of
depression. Assessment of quality of life in depressed
patients with the EQ-5D instrument is crucial input
information for calculating QALYs as an outcome
measure in economic evaluations and thus our results
are critical when assessing the cost-effectiveness of new
treatments for depression.
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